Payment overview · 2025
General Payments
$983.42
29 reported records · 12 companies
Healthcare provider profile · identity verified
Alicia E Novak
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · OLYPHANT, PA · NPI 1902314180
Verified facts
What the public records show
CMS Open Payments records show Alicia E Novak received $983.42 in general payments during 2025 across 29 reported records.
Medtronic, Inc. accounted for 29.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Synthroid, Xyosted.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 309 claims for Synthroid by this doctor in 2024.
Antares Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYOSTED as an associated drug or biological on 18015 records involving 7619 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xyosted by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 384 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 373 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 543 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$291.23 | 29.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $231.30 | 23.5% | 13 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $137.30 | 14.0% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $122.09 | 12.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $69.81 | 7.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.35 | 3.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.59 | 1.9% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $17.50 | 1.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.67 | 1.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.69 | 1.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.49 | 1.5% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $14.40 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $983.42 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $171.23 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $167.72 | 8 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $137.30 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $122.09 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $122.09 | 1 | 2025 |
Source payment records
|
|||||
| CATALYFT PL EXPANDABLE INTERBODY SYSTEM Normalized: catalyft pl expandable interbody system |
Device | Medtronic, Inc. | $120.00 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.30 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $49.08 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $35.71 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.35 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $34.10 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $14.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 384 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 373 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 543 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 309 | exact normalized | Medicare Part D |
| XYOSTED xyosted |
2025 | Xyosted | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
309 | 60 |
| Antares Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | XYOSTED open payments reported associated product |
CMS Open Payments — General Payments 18015 supporting records · 7619 recipient NPIs · example record 1235880452 |
Xyosted · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
384 | 72 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
373 | 61 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
169 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
543 | 101 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1031 | 216 |
| Metformin Hcl Er | Metformin Hcl | 544 | 143 |
| Ozempic | Semaglutide | 543 | 101 |
| Jardiance | Empagliflozin | 384 | 72 |
| Mounjaro | Tirzepatide | 373 | 61 |
| Metformin Hcl | Metformin Hcl | 340 | 90 |
| Synthroid | Levothyroxine Sodium | 309 | 60 |
| Glimepiride | Glimepiride | 260 | 57 |
| Novolog Flexpen | Insulin Aspart | 197 | 63 |
| Atorvastatin Calcium | Atorvastatin Calcium | 191 | 58 |
| Methimazole | Methimazole | 191 | 45 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 173 | 31 |
| Trulicity | Dulaglutide | 169 | 28 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 146 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 139 | 27 |
| Tradjenta | Linagliptin | 136 | 21 |
| Januvia | Sitagliptin Phosphate | 130 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 129 | 42 |
| Lisinopril | Lisinopril | 125 | 32 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 115 | 27 |
| Tresiba Flextouch U-100 | Insulin Degludec | 104 | 35 |
| Farxiga | Dapagliflozin Propanediol | 98 | 19 |
| Glipizide | Glipizide | 91 | 25 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 88 | 19 |
| Glipizide Er | Glipizide | 85 | 25 |
| Simvastatin | Simvastatin | 81 | 19 |
| Humalog Kwikpen U-100 | Insulin Lispro | 79 | 29 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 77 | 19 |
| Tresiba Flextouch U-200 | Insulin Degludec | 72 | 21 |
| Losartan Potassium | Losartan Potassium | 70 | 16 |
| Nateglinide | Nateglinide | 69 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 57 | 17 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 51 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 49 | 13 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 48 | suppressed |
| Unithroid | Levothyroxine Sodium | 48 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 46 | 11 |
| Liothyronine Sodium | Liothyronine Sodium | 46 | 11 |
| Droplet Pen Needle | Pen Needle, Diabetic | 45 | 20 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 12 |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 43 | 13 |
| Armour Thyroid | Thyroid,pork | 42 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 42 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 41 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 39 | suppressed |
| Gabapentin | Gabapentin | 38 | 11 |
| Vascepa | Icosapent Ethyl | 34 | suppressed |
| Humalog | Insulin Lispro | 33 | suppressed |
| Novolog | Insulin Aspart | 30 | 11 |
| Invokana | Canagliflozin | 29 | suppressed |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Omeprazole | Omeprazole | 27 | suppressed |
| Testosterone | Testosterone | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Baqsimi | Glucagon | 17 | 13 |
| Calcitriol | Calcitriol | 17 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 16 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 16 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Niacin Er | Niacin | 16 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 16 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Admelog Solostar | Insulin Lispro | 14 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 14 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Alogliptin-Pioglitazone | Alogliptin Benz/Pioglitazone | 13 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 13 | suppressed |
| Np Thyroid | Thyroid,pork | 13 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 13 | suppressed |
| Xyosted | Testosterone Enanthate | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 11 | suppressed |
| Propylthiouracil | Propylthiouracil | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $983.42 · 29 records | Medtronic, Inc. | CAPVAXIVE, CATALYFT PL EXPANDABLE INTERBODY SYSTEM, CeQur Simplicity, FREESTYLE LIBRE 3, GARDASIL 9, General - Pain Management, JARDIANCE, MOUNJARO, OPSUMIT, Ozempic, REPATHA, Rybelsus, SYMPLICITY G3, SYNTHROID, UBRELVY, UPTRAVI, VOQUEZNA, VRAYLAR, XYOSTED, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error